The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 02 May 2017 it purchased 100,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 5p per Ordinary Share (the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,143,715 equivalent to 18.37% of Proteome Sciences' total issued share capital.
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 27 April 2017 it purchased 100,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares" and the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,043,715 equivalent to 18.34% of Proteome Sciences' total issued share capital.
At the Company’s AGM held today the Chairman, Christopher Pearce, made the following statement: “As stated in our recent results, we expect 2017 to be a transformational year for Proteome Sciences. The combination of strong revenue growth during 2016 and operational initiatives to simplify our strategy, consolidate our resources and broaden our commercial capability, have put the Company in a good position to take advantage of the increasing opportunities afforded by quantitative proteomics. Trading remains in line with management expectations.”
Proteome Sciences plc (AIM:PRM) announces that on 7 April 2017, Ian Pike, Chief Scientific Officer of the Company and a former employee exercised 165,583 and 158,308 options over ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) respectively.
The Options represent 6.17% of the current issued share capital of the Company and lapse on 3 April 2027.
Richard Dennis commented: “I have been involved with proteins throughout my commercial career and am excited to be joining Proteome Sciences at this time. Never has the ‘power of the protein’ been better understood by, and more important to, the scientific community. Proteome Sciences can fully exploit this potential and I look forward to leading the commercial team to achieve this.”
Dr. Jeremy Haigh, Chief Executive remarks: "Enabling technologies such as ours afford us a tremendous opportunity… I am confident that we now have appropriate skills in the right locations pursuing a viable strategy for success. I look forward to further progress and substantial revenue growth in 2017."
Jeremy Haigh, Chief Executive of Proteome Sciences, commented: “While we are satisfied with solid progress during 2016, there is clearly much yet to do if we want to realise the full commercial value of our proteomic technologies. The Company is in a transition phase as we seek to expand our customer base to secure larger and more durable contracts for our services. The recent decision to consolidate our laboratory facilities in Frankfurt was difficult given our UK heritage but we firmly believe it to be in the best interests of the Company and our shareholders. We look forward to healthy progress during 2017, to the imminent arrival of our new Chief Commercial Officer, and to providing further updates through the course of the year.”
After a strong first half, progress continued throughout the rest of the year with results in line with expectations. Buoyed by robust sales of our TMT® reagents and the associated royalties, unaudited revenues during the full year increased by 46%.
Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Sciences Fund, of which Martin Diggle, a non-executive director of the Company, is a director and partner, that today, it purchased 105,590 ordinary shares of 1 pence each at 5.5 pence per Ordinary Share.